Trial Profile
A 4-week Dose-finding, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety of Different Doses of Rupatadine Compared to Placebo in the Treatment of Chronic Idiopathic Urticaria
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Rupatadine (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Uriach
- 12 Apr 2014 New trial record